Literature DB >> 20138866

Detection of matrix metallopeptidase-9-like proteins in Trypanosoma cruzi.

Ana Cristina Nogueira de Melo1, Edilma Paraguai de Souza, Camila Guarany Ramalho Elias, André Luis Souza dos Santos, Marta Helena Branquinha, Cláudia Masini d'Avila-Levy, Flávia Coelho Garcia dos Reis, Tatiana Ferreira Rocha Costa, Ana Paula Cabral de Araujo Lima, Mirian Cláudia de Souza Pereira, Maria Nazareth Leal Meirelles, Alane Beatriz Vermelho.   

Abstract

In this study, the cell-associated and extracellular peptidases of Trypanosoma cruzi grown in modified Roitman's complex (MRC) medium were analyzed by measuring peptidase activity in gelatin-containing zymograms. Our results showed that the cell-associated peptidases as well as peptidases extracellularly released by T. cruzi displayed two distinct proteolytic classes: cysteine and metallopeptidase activities. The major cysteine peptidase, cruzipain, synthesized by T. cruzi cells was detected in cellular parasite content, as a 50kDa reactive polypeptide, after probing with anti-cruzipain antibody. In addition, metallo-type peptidases belonging to the matrix metallopeptidase-9 (MMP-9) family were revealed, after Western blotting, as a 97kDa protein band in cellular extract and an 85kDa polypeptide in both cellular and secreted parasite extracts. The MMP-9-like activity present in cells and spent culture medium was immunoprecipitated by an anti-MMP-9 polyclonal antibody. The surface location of MMP-9-like proteins in T. cruzi was also evidenced by means of flow cytometry analysis. Furthermore, doxycycline that has direct MMP-9 inhibiting properties in vitro, inhibited MMP-9-like activities in gel zymography, immunoprecipitation and flow cytometry analyses. This is the first report of the presence of MMP-9-like molecules in T. cruzi. The presence of a matrix extracellular-degrading enzyme may play a role in the T. cruzi-host cell interaction, making this enzyme a potential target for future drug development against this pathogenic trypanosomatid.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138866     DOI: 10.1016/j.exppara.2010.01.023

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  6 in total

1.  Characterization of metalloproteases and serine proteases of Toxoplasma gondii tachyzoites and their effect on epithelial cells.

Authors:  Carlos J Ramírez-Flores; Rosalba Cruz-Mirón; Rossana Arroyo; Mónica E Mondragón-Castelán; Tais Nopal-Guerrero; Sirenia González-Pozos; Emmanuel Ríos-Castro; Ricardo Mondragón-Flores
Journal:  Parasitol Res       Date:  2018-12-01       Impact factor: 2.289

2.  Molecular imaging, biodistribution and efficacy of mesenchymal bone marrow cell therapy in a mouse model of Chagas disease.

Authors:  Antonio C Campos de Carvalho; David C Spray; Linda A Jelicks; Herbert B Tanowitz; Vera Maria Peters; Rosalia Mendez-Otero
Journal:  Microbes Infect       Date:  2014-09-16       Impact factor: 2.700

3.  Host-parasite interaction: parasite-derived and -induced proteases that degrade human extracellular matrix.

Authors:  Carolina Piña-Vázquez; Magda Reyes-López; Guillermo Ortíz-Estrada; Mireya de la Garza; Jesús Serrano-Luna
Journal:  J Parasitol Res       Date:  2012-06-26

Review 4.  Tracking stem cells with superparamagnetic iron oxide nanoparticles: perspectives and considerations.

Authors:  Gustavo Torres de Souza; Ruy Andrade Louzada; Paulo Henrique Rosado-de-Castro; Rosalia Mendez-Otero; Antonio Carlos Campos de Carvalho
Journal:  Int J Nanomedicine       Date:  2017-01-25

5.  Current understanding of the Trypanosoma cruzi-cardiomyocyte interaction.

Authors:  Claudia M Calvet; Tatiana G Melo; Luciana R Garzoni; Francisco O R Oliveira; Dayse T Silva Neto; Maria N S L; L Meirelles; Mirian C S Pereira
Journal:  Front Immunol       Date:  2012-10-30       Impact factor: 7.561

6.  Regulation and use of the extracellular matrix by Trypanosoma cruzi during early infection.

Authors:  Pius N Nde; Maria F Lima; Candice A Johnson; Siddharth Pratap; Fernando Villalta
Journal:  Front Immunol       Date:  2012-11-06       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.